eligibility_summary
Inclusion: Consent, 18–75, ECOG 0–1, survival ≥12 wks, colorectal adenocarcinoma, RAS/BRAF WT, limited, measurable liver-only mets, primary tumor resectable/resected, no prior therapy for liver mets, adequate marrow, liver, renal, cardiac (LVEF≥50%), coagulation, pulmonary, contraception. Exclusion: allergy, prior anti-cancer/RT or concurrent trial, recent major surgery, extrahepatic disease/unresectable nodes/recurrence or vessel invasion risk, other cancer ≤5y, autoimmune/immunodeficiency (except controlled hypothyroid/T1D) or immunosuppression, recent thrombosis, significant CV disease, active infection/effusions, active HBV/HCV or proteinuria, severe lung disease, pregnancy/lactation, recent live vaccine/other investigational therapy, investigator discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm phase II trial in RAS/BRAF wild-type unresectable liver-metastatic colorectal cancer testing: 1) Adebrelimab, an anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD-L1 interaction with PD-1/B7.1 to restore cytotoxic T-cell activity, 2) Cetuximab, an anti-EGFR IgG1 monoclonal antibody that inhibits EGFR signaling (RAS–MAPK/PI3K pathways) and can induce ADCC via NK cells, 3) Chemotherapy: FOLFOX6 (oxaliplatin: platinum DNA crosslinker, 5-fluorouracil: pyrimidine analog inhibiting thymidylate synthase, leucovorin: enhances 5-FU) or FOLFIRI (irinotecan: topoisomerase I inhibitor, plus 5-FU/leucovorin) to kill rapidly dividing tumor cells. Targets/pathways: PD-1/PD-L1 on tumor/immune cells, EGFR on tumor cells (effective in RAS/BRAF WT), DNA replication/repair machinery, and immune effector functions (T cells, NK cell–mediated ADCC).